Clinical Trial Update: A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density [Phase 2]

View source ↗

Summary

Phase 2 multicenter randomized, placebo-controlled pilot study using microCT to estimate the effects of denosumab (AMG 162) and alendronate sodium on bone miner…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• ALENDRONATE SODIUM (ALENDRONATE SODIUM)
• Denosumab (denosumab)

Snippet

Sponsor: Amgen | Conditions: Postmenopausal Osteoporosis | Phase 2 | Status: COMPLETED | Results posted: 2010-01-27